CORONA Remedies Share Price
2106.70-21.10 (-0.99%)
+46.46% past 1 Year
News
Corona Remedies to host analyst and investor meet on August 26, 2026
Equity
CORONA
Corona Remedies posts higher Q1 EBITDA and improved margin
Equity
CORONA
Corona Remedies reports strong year-on-year revenue growth in Q1 results
Equity
CORONA
Corona Remedies reports higher first quarter net profit on revenue growth
Equity
CORONA
Corona Remedies starts EU-GMP certified women’s hormone facility in Ahmedabad
Equity
CORONA
Corona Remedies informs about investor meetings
Equity
CORONA
CORONA Remedies rises on getting EU-GMP certification for Hormone manufacturing facility
Equity
CORONA
CORONA Remedies gets EU-GMP certification for Hormone manufacturing facility
Equity
CORONA
CORONA Remedies - Quaterly Results
Equity
CORONA
Corona Remedies Announces Final Dividend of Rs 10 Per Share
Equity
CORONA
Corona Remedies Reports Q4 EBITDA Growth to Rs 61 Crores, Margin Slightly Declines YoY
Equity
CORONA
Corona Remedies Q4 Net Profit Rises 44% YoY to Rs 45.10 Crores, Revenue Up 20% to Rs 353 Crores
Equity
CORONA
CORONA Remedies reports Profit after tax of 45.05 Crores, in the March 2026 quarter
Equity
CORONA
Corona Remedies Reports OCF to EBITDA Ratio of 87%, Enabling Further Acquisitions.
Equity
CORONA
Corona Remedies Reports Rs 112 Cr Cash as of Dec 31, Targets 20-25% CAGR for Wpladone Over 3 Years.
Equity
CORONA
CORONA Remedies acquires ‘Wokadine’ from Dr. Reddy’s Laboratories
Equity
CORONA
Corona Remedies informs about analyst meet
Equity
CORONA
CORONA Remedies - Quaterly Results
Equity
CORONA
Corona Remedies Reports Strong Q3 EBITDA Growth with Margin Expansion YoY.
Equity
CORONA
Corona Remedies Q3FY26 Net Profit at Rs 41.30 Crores Down 7.8% YoY, Revenue Up 14.5% to Rs 340 Crores.
Equity
CORONA